热门资讯> 正文

分子蛋白生物技术报告财年业绩

2026-03-20 02:59

Moleculin Biotech, Inc.(MBRX) 0

Moleculin Biotech press release (MBRX): FY EPS of -$28.42.
As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 million.

More on Moleculin Biotech

Moleculin Biotech secures $8.3M from warrant exercises, issues new 5-year warrants
Seeking Alpha’s Quant Rating on Moleculin Biotech
Historical earnings data for Moleculin Biotech
Financial information for Moleculin Biotech

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。